Unacknowledged Casualties
The ADF Quinoline Drug Trials and the Families Left Behind
The Other Casualty: How ADF Drug Trials Harmed Soldiers and Their Families
Between 1998 and 2002, approximately 3,000 members of the Australian Defence Force were given powerful antimalarial drugs — mefloquine and tafenoquine — during deployments to East Timor and Bougainville. In significant part, these were clinical drug trials conducted by the Army Malaria Institute. The personnel who received the drugs were not always adequately informed of the risks. Many were not informed at all.
Both drugs are now recognised by regulatory agencies in Australia, the United States, and Europe as carrying substantial neuropsychiatric risk. The US Food and Drug Administration issued its strongest possible warning for mefloquine in 2013. Research conducted by the same institute that developed tafenoquine found it to be more neurotoxic than mefloquine.
The harms documented among affected veterans include chronic depression, paranoia, psychosis, personality change, dissociation, aggression, and suicide.
They also include domestic violence.
This site addresses what that means for the people who were not on deployment — the partners and spouses who came home to someone changed, who lived with consequences they did not choose and were never warned about, and who have never been recognised by any institution as having been harmed.
The spouse is not a footnote in this story. She is its other casualty.
Where Would You Like to Start?
For journalists and researchers
The science is real, the regulatory record is public, and the institutional failures are documented. Begin with The Issue for an overview, or go directly to The Drugs for the scientific and regulatory foundation. Documented Cases and System Failures are designed with your verification needs in mind. The full research report is available to download below.
For affected families
If you are a partner or former partner of an ADF veteran who served in East Timor or Bougainville, and you recognise something of your experience in what this site describes, you are not alone and you are not invisible here. Start with The Spouse — a page written specifically about the long-term effects on partners — or with The Household, which describes the behavioural patterns that have affected so many families. A dedicated page For Families is also available, with information about support.
For policymakers and legal professionals
The gaps in the current system are specific, documented, and in several cases addressable through existing legislative and regulatory mechanisms. System Failures analyses what each relevant institution currently cannot see or do. Misdiagnosisaddresses the treatment and entitlements consequences of the wrong diagnosis. What Must Change sets out the findings and seven specific recommendations. The International Record provides comparative context.
Make it stand out.
It all begins with an idea. Maybe you want to launch a business. Maybe you want to turn a hobby into something more. Or maybe you have a creative project to share with the world. Whatever it is, the way you tell your story online can make all the difference.
This site uses four evidential registers, which are identified on each page:
A Note on the Evidence
Established fact — findings confirmed by peer-reviewed science, regulatory agency determinations, or official parliamentary and coronial records.
Documented case evidence — cases or patterns recorded in advocacy submissions, parliamentary testimony, or media records, which have not been independently verified by this site but are accurately represented as sourced.
Plausible mechanism — a biological or clinical pathway that is consistent with the scientific literature and offers a credible explanation, but has not yet been demonstrated by a direct study in this specific population.
Area of uncertainty — questions the current evidence does not resolve, identified honestly rather than papered over.
The central claim of this site — that the neuropsychiatric effects of mefloquine and tafenoquine are a serious, under-investigated contributor to domestic harm in affected ADF families — rests on established regulatory fact and a plausible neurobiological mechanism. The direct causal chain in individual cases is not asserted beyond what the literature supports.
The Royal Commission and What Remains
In September 2024, the Royal Commission into Defence and Veteran Suicide tabled its Final Report. Volume 4, Chapter 22 addressed mefloquine and tafenoquine directly, and recommended that Defence and the Department of Veterans' Affairs establish a brain injury program for serving and ex-serving members exposed to these drugs. In December 2024, the Australian Government accepted or agreed in principle to 104 of the Commission's 122 recommendations, and work on the brain injury program is reported to be underway.
This is a significant development. It is not the end of the story.
The Royal Commission's recommendations address veterans. They do not yet extend formal recognition to the partners and families who have carried their own share of the consequences. The brain injury program's scope, funding, and delivery remain to be tested. The systemic gaps in domestic violence services, family law, and veterans' entitlements that this site documents remain in place.
This site builds on the Royal Commission's findings. It asks what comes next.
Download the Full Report
The complete research report — Unacknowledged Casualties: Quinoline Antimalarial Drug Toxicity, Domestic Violence, and Secondary Harm to Spouses and Partners of ADF East Timor Veterans — is available for download.
[Download the report (PDF)]
The report includes full source references, methodological notes, and the complete findings and recommendations on which this site is based.
This site was prepared in 2026. It incorporates findings from the Royal Commission into Defence and Veteran Suicide (Final Report, September 2024) and the Australian Government response (December 2024).